Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¹ÙÀÌ¿À¸¶Ä¿ÀÇ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð ¹× Á¡À¯À², ¿¹Ãø(2025-2032³â)
Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1709466
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 301 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,518,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,464,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,855,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 42¾ï 9,043¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2032³â¿¡ CAGR 4.50%·Î È®´ë

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ¿ªÇÐ

Æó¼¶À¯Áõ ¹ßº´·ü Áõ°¡·Î Áø´Ü¿ë ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ Ãß¼¼

Æó¼¶À¯Áõ(PF) À¯º´·ü Áõ°¡´Â ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Àεµ¿Í °°Àº ±¹°¡¿¡¼­´Â Ư¹ß¼º Æó¼¶À¯Áõ(IPF)ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Àα¸ 10¸¸ ¸í´ç 14-43¸íÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ¼ö Áõ°¡´Â Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÇÑ Á¶»ç¿¡ µû¸£¸é IPF´Â ±¹³» Àüü °£Áú¼º ÆóÁúȯ(ILD)ÀÇ ¾à 17%¸¦ Â÷ÁöÇϸç, ÀÌ ÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇϰí È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â °ÍÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Çª³×¿Í °°Àº Áö¿ª¿¡¼­´Â IPF ȯÀÚ°¡ ¸Å³â 5-7%¾¿ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÷´Ü Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ Æó¼¶À¯Áõ ȯÀÚ°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü, Áúº´ ÁøÇà ¸ð´ÏÅ͸µ, Ä¡·á È¿°ú Æò°¡¸¦ À§ÇÑ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ Çʿ伺ÀÌ ±× ¾î´À ¶§º¸´Ù ³ô¾ÆÁö¸é¼­ ÀÌ ½ÃÀå¿¡¼­ÀÇ Çõ½Å¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÁÖ¿ä °í·Á»çÇ×

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032) µ¿¾È ¿¬Æò±Õ ¾à 4.50%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿ À¯Çüº°·Î´Â Áø´Ü¿ë ¹ÙÀÌ¿À¸¶Ä¿°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº°·Î´Â Áø´ÜÀÌ 2024³â ÁÖ¿ä ¿ëµµÀÔ´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â Áø´Ü½ÇÇè½ÇÀÌ 2024³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚÀÓÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÔ¿øÀÔ´Ï´Ù.

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ¼¼°è ½ÃÀåÀº ¹ÙÀÌ¿À¸¶Ä¿ À¯Çü, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿ÀÇ À¯Çü¿¡ µû¶ó ½ÃÀåÀº Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿, ¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿, ¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß´Â Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ °¡Àå µÎµå·¯Áö°í Áß¿äÇÑ ºÐ¾ßÀÔ´Ï´Ù. Æó¼¶À¯Áõ(PF)ÀÇ Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿´Â ÀÌ °úÁ¤¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â Æó¼¶À¯ÁõÀÇ Ãʱ⠴ܰ迡¼­ Æó¼¶À¯ÁõÀÇ Á¸À縦 È®ÀÎÇÏ¿© °³ÀÔÀ» ÅëÇØ ÁúȯÀÇ ÁøÇàÀ» ´ÊÃâ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Ư¹ß¼º Æó¼¶À¯Áõ(IPF)°ú °°Àº ÁúȯÀº ´Ù¸¥ Æó Áúȯ°úÀÇ À¯»ç¼ºÀ¸·Î ÀÎÇØ Áø´ÜÀÌ ¾î·Æ±â ¶§¹®¿¡ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿´Â PF¿Í ´Ù¸¥ ÁúȯÀ» ±¸º°ÇÏ¿© º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Áø´Ü¿¡ µµ¿òÀÌ µÇ¹Ç·Î ÀÓ»ó¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹°ú °°Àº Áö¿ª¿¡¼­´Â PF¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¹ßº´·üÀÌ ³ô±â ¶§¹®¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü Åø¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä´Â º¸´Ù È¿À²ÀûÀÎ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿¬±¸°³¹ßÀ» ÃËÁøÇÏ¿© Áø´Ü¿ë ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß°¡ ½ÃÀå ¿ìÀ§¸¦ À¯ÁöÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î Áø´Ü, Ä¡·á ¸ð´ÏÅ͸µ, ÀǾàǰ °³¹ßÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ °¡Àå Áß¿äÇÑ ºÐ¾ß´Â Áø´Ü ºÐ¾ßÀÔ´Ï´Ù. Æó¼¶À¯Áõ(PF)ÀÇ Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Àû½Ã¿¡ Ä¡·áÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Æó¼¶À¯Áõ, ƯÈ÷ Ư¹ß¼º Æó¼¶À¯Áõ(IPF)Àº ´Ù¸¥ ÆóÁúȯ°ú Áõ»óÀÌ À¯»çÇÏ¿© ¿ÀÁøµÇ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿´Â À¯»ç Áúȯ°úÀÇ °¨º°¿¡ ÇʼöÀûÀ̸ç, KL-6, SP-D, CCL18°ú °°Àº ¹ÙÀÌ¿À¸¶Ä¿´Â ÁúȯÀÇ ÁøÇàÀ» ´ÊÃß±â À§ÇÑ °³ÀÔÀÌ °¡Àå È¿°úÀûÀÎ Ãʱ⠴ܰ迡¼­ PFÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÑ Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ßÀ» À§ÇÑ »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸±â°ü°ú ÀÇ·áÁøÀÌ Á¶±â Áø´ÜÀ» Áß½ÃÇÏ´Â °¡¿îµ¥, Áø´Ü ¿ëµµ´Â Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå°ú Çõ½ÅÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì´Â ÷´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÆóÁúȯ À¯º´·ü, Áö¼ÓÀûÀÎ ¿¬±¸ ±¸»ó¿¡ ÈûÀÔ¾î Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ÃÖ°í ¼öÁØÀÇ ¿¬±¸±â°ü°ú Á¦¾à»çÀÇ Á¸Àç, ÀÓ»ó½ÃÇè Áõ°¡¿¡ ÈûÀÔ¾î ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ¾à 20¸¸ ¸íÀÌ Æ¯¹ß¼º Æó¼¶À¯Áõ(IPF) Áø´ÜÀ» ¹Þ¾ÒÀ¸¸ç, Á¶±â ¹ß°ß ¹× Á¶±â °ü¸®¸¦ À§ÇÑ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)°ú °°Àº Á¤ºÎ ÇÁ·Î±×·¥Àº ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ½Äº° ¹× °ËÁõÀ» À§ÇÑ ¿¬±¸¿¡ ÀÚ±ÝÀ» Áö¿øÇÏ¿© ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ °­·ÂÇÑ ÀÇ·áºñ »óȯ Á¦µµ´Â »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿°¡ ÀÓ»ó Áø·á¿¡ Àû¿ëµÉ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áúº´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹Àº ÷´ÜÈ­µÈ ÀÇ·á ½Ã½ºÅÛ°ú ÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Áø´ÜÀ» ¹ÞÀº ȯÀÚ ¼ö°¡ 20¸¸ ¸íÀ» ³Ñ¾î¼­¸é¼­ Á¶±â ¹ß°ß, ¿¹ÈÄ ¿¹Ãø, Ä¡·á ¸ð´ÏÅ͸µÀ» À§ÇÑ È¿°úÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ Á¤ºÎ´Â ±¹¸³º¸°Ç¿ø(NIH) µîÀÇ ±â°üÀ» ÅëÇØ »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß°ßÇϱâ À§ÇÑ ¿¬±¸¿¡ ¸¹Àº ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, IPFÀÇ Áø´Ü Åø¿Í Ä¡·á¹ý °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ ¼Ö·ç¼ÇÀ» ÁøÇàÇϱâ À§ÇØ ¿¬±¸±â°ü°ú Àû±ØÀûÀ¸·Î Çù·ÂÇϰí ÀÖ´Â °­·ÂÇÑ Á¦¾à¾÷°èµµ ÀÌ ±¹°¡ÀÇ ÀÚ¶û°Å¸®ÀÔ´Ï´Ù.

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : °æÀï ±¸µµ

Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå °æÀï ±¸µµ´Â ´ëÇü Á¦¾à»ç ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö Àü¹® ±â¾÷ÀÇ Á¸Àç·Î Ư¡Áö¾îÁý´Ï´Ù. Genentech, F. Hoffman-La Roche, Gilead Sciences¿Í °°Àº ´ëÇü ±â¾÷Àº Æó Áúȯ¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¶»ç ¿ª·®°ú źźÇÑ Æ÷Æ®Æú¸®¿À¸¦ ¹ÙÅÁÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌµé ±â¾÷Àº ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼, ÀÓ»ó½ÃÇè ¼öÇà, Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÅëÇÕÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Biodesix¿Í Thermo Fisher Scientific°ú °°Àº ¼Ò±Ô¸ð »ý¸í°øÇÐ ±â¾÷µµ Æó¼¶À¯Áõ¿¡ ƯȭµÈ Çõ½ÅÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ Ç÷§Æû°ú Áø´Ü Åø·Î Å« ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÁõ°ú »ó¿ëÈ­¸¦ °¡¼ÓÈ­Çϱâ À§ÇÑ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ Àü·«Àû Á¦ÈÞ¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ÁøÈ­¿Í ÇÔ²² ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀ» äÅÃÇÏ´Â ±â¾÷ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °æÀïÀÌ ´õ¿í Ä¡¿­ÇØÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±¸µµ

Á¦7Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¹ÙÀÌ¿À¸¶Ä¿ÀÇ À¯Çüº°

Á¦8Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¿ëµµº°

Á¦9Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : Æó¼¶À¯Áõ ¹ÙÀÌ¿À¸¶Ä¿ ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.

Pulmonary fibrosis biomarkers are biological indicators that help in the diagnosis, monitoring, and prognosis of pulmonary fibrosis, a progressive lung disease characterized by scarring of lung tissue. These biomarkers can be proteins, genes, or other molecules present in blood, urine, or tissue samples. They assist in understanding the disease's progression and response to treatment. Biomarkers such as KL-6, SP-D, and CCL18 are often used to monitor disease activity and predict outcomes. Research into pulmonary fibrosis biomarkers is crucial for early detection, personalized treatments, and the development of new therapies. These biomarkers also help differentiate pulmonary fibrosis from other lung diseases with similar symptoms. As the disease can be difficult to diagnose, biomarkers provide valuable insights for clinicians to make more accurate decisions. With ongoing studies, these biomarkers are increasingly seen as essential tools for better patient management.

Pulmonary Fibrosis Biomarkers Market- Market Dynamics

Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.

The increasing incidence of pulmonary fibrosis (PF) is a key driver for the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is rising, with estimates ranging between 14 to 43 per 100,000 people. This growing number of cases highlights the urgent need for early and accurate diagnosis. A study revealed that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, emphasizing the importance of detecting the condition early to manage it effectively. Furthermore, regions like Pune have seen a 5-7% annual increase in IPF cases, which further underscores the demand for advanced diagnostic tools. As pulmonary fibrosis cases continue to rise globally, the need for reliable biomarkers that can diagnose, monitor disease progression, and assess treatment efficacy is more critical than ever, driving the demand for innovation in this market.

Pulmonary Fibrosis Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2025-2032)

Based on Type of Biomarkers segmentation, Diagnostic Biomarkers was predicted to show maximum market share in the year 2024

Based on application segmentation, Diagnosis was the leading application in 2024

Based on End-user segmentation, Diagnosis laboratories was the leading End-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:

The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.

The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most prominent and significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes, and diagnostic biomarkers play a vital role in this process. These biomarkers are essential in identifying the presence of PF at its early stages, when intervention can still slow disease progression. With diseases like idiopathic pulmonary fibrosis (IPF) being challenging to diagnose due to their similarities with other lung conditions, diagnostic biomarkers help differentiate PF from other diseases, leading to quicker and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly being used in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The growing awareness of PF and its high incidence rate in regions like the U.S. further intensifies the need for reliable diagnostic tools. This demand is driving the research and development of new, more efficient biomarkers, ensuring that the diagnostic biomarkers segment remains dominant in the market.

The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes and enabling timely treatments. Since PF, particularly idiopathic pulmonary fibrosis (IPF), shares symptoms with other lung diseases, it is often misdiagnosed, making diagnostic biomarkers vital for distinguishing it from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are commonly used in clinical practice for their ability to detect PF at early stages, when interventions are most effective in slowing disease progression. With the rising prevalence of PF, there is an increasing demand for precise diagnostic tools, driving the focus on developing new biomarkers for early detection. Moreover, as research institutions and healthcare providers emphasize early diagnosis, the diagnostic application remains central to the growth and innovation in the pulmonary fibrosis biomarkers market.

Pulmonary Fibrosis Biomarkers Market- Geographical Insights

North America is a leading region in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and ongoing research initiatives. The United States, in particular, has a significant share in the market, supported by the presence of top-tier research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a strong demand for diagnostic biomarkers to aid early detection and management. Furthermore, government programs, like the National Institutes of Health (NIH), are funding research to identify and validate biomarkers, boosting innovation. The region's strong healthcare reimbursement systems also ensure that emerging biomarkers are adopted into clinical practice. Additionally, rising awareness about the disease and advancements in personalized medicine are further propelling market growth.

The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare system and substantial investment in medical research. With over 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF), the demand for effective biomarkers for early detection, prognosis, and treatment monitoring is growing rapidly.

The U.S. government, through agencies like the National Institutes of Health (NIH), is heavily funding research to discover new biomarkers. This, in turn, accelerates the development of diagnostic tools and therapies for IPF. The country also boasts a robust pharmaceutical industry that actively collaborates with research institutions to advance biomarker-driven solutions

Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:

The competitive landscape of the Pulmonary Fibrosis Biomarkers market is marked by the presence of both established pharmaceutical giants and specialized biotech companies. Major players like Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market due to their extensive research capabilities and robust portfolios in pulmonary diseases.

These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment protocols. At the same time, smaller biotech firms like Biodesix and Thermo Fisher Scientific are making significant strides with innovative biomarker platforms and diagnostic tools tailored for pulmonary fibrosis. The competitive environment is also driven by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As the market evolves, companies are increasingly adopting personalized medicine approaches, further intensifying competition.

Recent Developments:

In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening disease. This designation expanded the company's product portfolio.

In March 2020, Bristol Myers Squibb entered into a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. The partnership aimed to accelerate the development of targeted therapies for this challenging condition, reflecting the company's commitment to enhancing patient outcomes. This initiative helped boost sales and revenue.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Pulmonary Fibrosis Biomarkers Market Overview

2. Executive Summary

3. Pulmonary Fibrosis Biomarkers Key Market Trends

4. Pulmonary Fibrosis Biomarkers Industry Study

5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions

6. Pulmonary Fibrosis Biomarkers Market Landscape

7. Pulmonary Fibrosis Biomarkers Market - By Type of Biomarkers

8. Pulmonary Fibrosis Biomarkers Market - By Application

9. Pulmonary Fibrosis Biomarkers Market - By End-user

10. Pulmonary Fibrosis Biomarkers Market- By Geography

11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â